Although a relatively new therapeutic concept, SL strategies have already begun to enter the clinic as breast and ovarian cancers harboring BRCA1/2 (Breast Cancer Type 1/2 Susceptibility Protein) defects are now being targeted with PARP1 (Poly [ADP-Ribose] Polymerase 1) inhibitors like Olaparib. Here, PARP1 is linked to breast carcinoma.